https://www.businesswire.com/news/home/20240501555976/en/Avilar-Therapeutics-to-Present-Preclinical-Data-for-MTAC-M6PR-Targeting-Chimera-Extracellular-Protein-Degrader-Platform-at-the-American-Association-of-Immunologists-Annual-Meeting
Avilar Therapeutics to Present Preclinical Data for MTAC (M6PR Targeting Chimera) Extracellular...
Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced it will present preclinical proof-of-concept d...
preclinical data